Humoral response after three doses of BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Dialysis patients are at increased risk of severe COVID-19 infections (1). Therefore, there are considered as being a priority population for COVID-19 vaccination. Because immune responses against vaccines are considerably reduced in this population (2), a vaccination strategy including three doses of vaccine has been recommended for dialysis patients. However, few data exist concerning humoral response to SARS-coV-2 vaccination with three doses of BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis (HD).
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: letters to the editor Source Type: research